7/6/2022 8:05:07 AM
Immunome Says Its COVID-19 Cocktail Retains Neutralizing Activity Against Most Prevalent Omicron Subvariants In US
6/9/2022 8:18:56 AM
Immunome Begins Phase 1b Study Of IMM-BCP-01 For COVID-19
5/19/2022 8:10:39 AM
Immunome :Data Shows COVID-19 Antibody Cocktail Potently
Clears Omicron BA.1 Variant In Hamster Model
3/11/2022 8:06:49 AM
FDA Lifts Clinical Hold On Immunome's IMM-BCP-01 IND Application For Treatment Of COVID-19; Stock Up
11/29/2021 7:11:57 AM
Immunome Says Submits IND Application For IMM-BCP-01 For Treatment Of COVID-19
9/7/2021 7:27:06 AM
Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes SARS-CoV-2 Lambda And Delta Plus Variants In Pre-clinical Testing
6/17/2021 7:20:33 AM
Immunome Appoints Franklyn Prendergast To Board
5/20/2021 7:55:02 AM
Immunome Announces $4.3 Mln Increase Awarded By DOD For Continued Development Of An Antibody Cocktail
5/12/2021 6:21:40 AM
Immunome Q1 Loss Per Share $0.37 Vs Loss Per Share $2.44 Last Year
4/20/2021 8:05:45 AM
Immunome Appoints Corleen Roche As CFO
3/30/2021 8:13:23 AM
Immunome Appoints Dennis Giesing To The Role Of Chief
Development Officer
3/23/2021 7:11:58 AM
Immunome Advances Proprietary Antibody Against IL-38 Into IND-enabling Studies And Expects Filing An IND In H2 2021